Definitive Healthcare Corp. (NASDAQ:DH) Receives $3.94 Consensus Price Target from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has earned an average recommendation of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $3.5214.

DH has been the topic of several research reports. Morgan Stanley restated an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. William Blair raised Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. Canaccord Genuity Group decreased their price objective on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday, February 27th. Finally, Stephens lowered their price objective on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its position in shares of Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after acquiring an additional 7,404,363 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Definitive Healthcare by 1.6% during the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock valued at $8,417,000 after purchasing an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Definitive Healthcare by 11.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after purchasing an additional 127,055 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Definitive Healthcare by 23.7% in the 2nd quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock valued at $3,001,000 after purchasing an additional 147,599 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in shares of Definitive Healthcare by 0.4% in the 2nd quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after buying an additional 3,066 shares in the last quarter. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Trading Up 1.8%

Shares of Definitive Healthcare stock opened at $1.16 on Friday. Definitive Healthcare has a 1 year low of $1.07 and a 1 year high of $4.70. The company’s fifty day simple moving average is $2.13 and its 200-day simple moving average is $2.83. The company has a market cap of $163.98 million, a price-to-earnings ratio of -0.93 and a beta of 1.66. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.41.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.